Crossmark Global Holdings Inc. Has $4.23 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Crossmark Global Holdings Inc. raised its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 36.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,827 shares of the company's stock after purchasing an additional 6,896 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in DaVita were worth $4,234,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in DVA. Texas Permanent School Fund Corp raised its position in shares of DaVita by 5.6% during the 1st quarter. Texas Permanent School Fund Corp now owns 11,133 shares of the company's stock valued at $1,537,000 after acquiring an additional 588 shares in the last quarter. Empowered Funds LLC acquired a new stake in DaVita during the first quarter worth about $404,000. Oppenheimer & Co. Inc. bought a new position in DaVita in the first quarter worth about $703,000. Forsta AP Fonden boosted its stake in DaVita by 50.3% in the first quarter. Forsta AP Fonden now owns 23,600 shares of the company's stock valued at $3,258,000 after acquiring an additional 7,900 shares during the period. Finally, Sei Investments Co. raised its position in shares of DaVita by 21.3% during the 1st quarter. Sei Investments Co. now owns 41,952 shares of the company's stock worth $5,790,000 after purchasing an additional 7,371 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Up 0.7 %

DaVita stock traded up $1.12 during mid-day trading on Tuesday, hitting $155.60. The company's stock had a trading volume of 107,221 shares, compared to its average volume of 815,597. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a 52-week low of $84.64 and a 52-week high of $168.50. The firm's 50 day moving average is $157.22 and its 200 day moving average is $147.05. The company has a market cap of $12.76 billion, a PE ratio of 16.66, a price-to-earnings-growth ratio of 0.84 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the prior year, the business posted $2.85 earnings per share. The business's revenue for the quarter was up 4.6% compared to the same quarter last year. On average, analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares in the company, valued at $138,284,666.75. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares of the company's stock, valued at $36,299,008.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Javier Rodriguez sold 50,000 shares of the business's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 165,625 shares of company stock valued at $26,238,297 over the last ninety days. Corporate insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Barclays upped their price objective on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research report on Wednesday, August 7th. Truist Financial upped their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a report on Thursday, August 8th. Finally, TD Cowen raised their target price on DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a research report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.